Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin

Neuro-Oncology

Volumn 9, Issue 1, 2007, Pages 39-46

  Mora, Jaume ^a   Cruz, Ofelia ^a   Gala, Sandra ^a   Navarro, Ramon ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Chemotherapy; Childhood brain tumor; Cisplatin; Intramedullary astrocytoma; Irinotecan; Primary intramedullary spinal cord neoplasms

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; IRINOTECAN; METHOTREXATE; OPIATE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ARTICLE; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CASE REPORT; CHILDHOOD CANCER; COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; SPINAL CORD TUMOR; TUMOR VOLUME; INFANT; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; CAMPTOTHECIN; CISPLATIN; FEMALE; HUMANS; INFANT; MALE; SPINAL CORD NEOPLASMS; TREATMENT OUTCOME;

EID: 34047205697     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2006-026     Document Type: Article

References (47)

1. Allen, J.C., Aviner, S., Yates, A.J., Boyett, J.M., Cherlow, J.M., Turski, P.A., Epstein F., and Finlay, J.L. (1998) Treatment of high-grade spinal cord astrocytoma of childhood with "8-in-1" chemotherapy and radiotherapy. A pilot study of CCG-945. Children's Cancer Group. J. Neurosurg. 88, 215-220.
2. Blaney, S., Berg, S.L., Pratt, C., Weitman, S., Sullivan, J., Luchtman-Jones, L., and Bernstein, M. (2001) A phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group study. Clin. Cancer Res. 7, 32-37.
3. Bomgaars, L., Berg, S.L., and Blaney, S.M. (2001) The development of camptothecin analogs in childhood cancers. Oncologist 6, 506-516.
4. Bomgaars, L., Kerr, J., Berg, S., Kuttesch, J., Klenke, R., and Blaney, S.M. (2006) A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr. Blood Cancer 46, 50-55.
5. Bouffet, E., Pierre-Kahn, A., Marchal, J.C., Jouvet, A., Kalifa, C., Choux, M., Dhellemmes, P., Guerin, J., Tremoulet, M., and Mottolese, C. (1998) Prognostic factors in pediatric spinal cord astrocytoma. Cancer 83, 2391-2399.
6. Clayton, P.E., and Shalet, S.M. (1991) The evolution of spinal growth after irradiation. Clin. Oncol. (R. Coll. Radiol.) 3, 220-222.
7. Coggins, C.A., Elion, G.B., Houghton, P.J., Hare, C.B., Keir, S., Colvin, O.M., Bigner, D.D., and Friedman, H.S. (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother. Pharmacol. 41, 485-490.
8. Constantini, S., Miller, D.C., Allen, J.C., Rorke, L.B., Freed, D., and Epstein F.J. (2000) Radical excision of intramedullary spinal cord tumours: Surgical morbidity and long-term follow-up evaluation in 164 children and young adults. J. Neurosurg. Spine 93, 183-193.
9. Cosetti, M., Wexler, L.H., Calleja, E., Trippett, T., LaQuaglia, M., Huvos, A.C., Gerald, W., Healey, J.H., Meyers, P.A., and Gorlick, R. (2002) Irinotecan for pediatric solid tumors: The Memorial Sloan-Kettering experience. J. Pediatr. Hematol. Oncol. 24, 101-105.
10. Coull, J.A., Beggs, S., Boudreau, D., Boivin, D., Tsuda, M., Inoue, K., Gravel, C., Salter, M.W., and De Koninck, Y. (2005) BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438, 1017-1021.
11. Doireau, V., Grill, J., Zerah, M., Lellouch-Tubiana, A., Couanet, D., Chastagner, P., Marchal, J.C., Grignon, Y., Chouffai, Z., and Kalifa, C. (1999) Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP). Br. J. Cancer 81, 835-840.
12. Duffner, P.K., Horowitz, M.E., Krischer, J.P., Krischer, J.P., Friedman, H.S., Burger, P.C., Cohen, M.E., Sanford, R.A., Mulhern, R.K., James, H.E., Freeman, C.R., et al. (1993) Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N. Engl. J. Med. 328, 1725-1731.
13. Duffner, P.K., Horowitz, M.E., Krischer, J.P., Burger, P.C., Cohen, M.E., Sanford, R.A., Friedman, H.S., and Kun, L.E. (1999) The treatment of malignant brain tumors in infants and very young children: An update of the Pediatric Oncology Group experience. Neuro-Oncology 1, 152-161.
14. Foreman, N.K., Hay, T.C., and Handler, M. (1998) Chemotherapy for spinal cord astrocytoma. Med. Pediatr. Oncol. 30, 311-312.
15. Furman, W.L., Stewart, C.F., Poquette, C.A., Pratt, C.B., Santana, V.M., Zamboni, W.C., Bowman, L.C., Ma, M.K., Hoffer, F.A., Meyer, W.H., Pappo, A.S., Walter, A.W., and Houghton, P.J. (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J. Clin. Oncol. 6, 1815-1824.
16. Geyer, J.R., Finlay, J.L., Boyett, J.M., Wisoff, J., Yates, A., Mao, L., and Packer, R.J. (1995) Survival of infants with malignant astrocytomas: A report from the Children's Cancer Group. Cancer 75, 1045-1050.
17. Gnekow, A.K., Packer, R.J., and Kortmann, R.D. (2004) Astrocytic tumors, low grade: Treatment considerations by primary site and tumor dissemination. In: Walker, D.A., Perilongo, G., Punt, J.A.G., and Taylor, R.E. (Eds.), Brain and Spinal Tumors of Childhood. London: Arnold, pp. 259-276.
18. Goh, K.Y., Velasquez, L., and Epstein, F.J. (1997) Pediatric intramedullary spinal cord tumors: Is surgery alone enough? Pediatr. Neurosurg. 27, 34-39.
19. Gururangan, S., Cavazos, C.M., Ashley, D., Herndon II, J.E., Bruggers, C.S., Moghrabi, A., Scarcella, D.L., Watral, M., Tourt-Uhlig, S., Reardon, D., and Friedman, H.S. (2002) Phase II study of carboplatin in children with progressive low-grade gliomas. J. Clin. Oncol. 20, 2951-2958.
20. Hassall, T.E., Mitchell, A.E., and Ashley, D.M. (2001) Carboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: Three case studies and a review of the literature. Neuro-Oncology 3, 251-257.
21. Hertzberg, R.P., Caranfa, M.J., Holden, K.G., Jakas, D.R., Gallagher, G., Mattern, M.R., Mong, S.M., Bartus, J.O., Johnson, R.K., and Kingsbury, W.D. (1989) Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32, 715-720.
22. Houghton, P.J., and Santana, V.M. (2002) Clinical trials using irinotecan. J. Pediatr. Hematol. Oncol. 24, 84-85.
23. Houten, J.K., and Cooper, P.R. (2000) Spinal cord astrocytomas: Presentation, management and outcome. J. Neurooncol. 47, 219-224.
24. Innocenzi, G., Salvati, M., Cervoni, L., Delfini, R., and Cantore, G. (1997) Prognosis factors in intramedullary astrocytomas. Clin. Neurol. Neurosurg. 99, 1-5.
25. Isaacson, S.R. (2000) Radiation therapy and the management of intramedullary spinal cord tumors. J. Neurooncol. 47, 231-238.
26. Jallo, G.I., Freed, D., and Epstein, F. (2003) Intramedullary spinal cord tumors in children. Childs Nerv. Syst. 19, 641-649.
27. Kamiyama, H., Takano, S., Tsuboi, K., and Matsumura, A. (2005) Antiangiogenic effects of SN38 (active metabolite of irinotecan): Inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J. Cancer Res. Clin. Oncol. 131, 205-213.
28. Kleihues, P.D.R., Coons, S.W., and Burger, P.C. (2000) Astrocytic tumors. In: Kleihues, P., and Cavenee, W.B. (Eds.), Pathology and Genetics: Tumors of the Nervous System. World Health Organization Classification of Tumors. Lyon, France: IARC, pp. 27-28.
29. Kobayashi, K., Shinbara, A., Kamimura, M., Takeda, Y., Kudo, K., Kabe, J., Hibino, S., Hino, M., Shibuya, M., and Kudoh, S. (1998) Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. Cancer Chemother. Pharmacol. 42, 53-58.
30. Koshy, M., Paulino, A.C., Marcus Jr., R.B., and Ting, J. (2004) The effect of an extended source-to-skin distance in the treatment of the spinal field in children receiving craniospinal irradiation. Med. Dosim. 29, 7-10.
31. Kushner, B.H., Kramer, K., Modak, S., and Cheung, N.K. (2005) Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer 103, 858-862.
32. Lowis, S.P., Pizer, B.L., Coakham, H., Nelson, R.J., and Bouffet, E. (1998) Chemotherapy for spinal cord astrocytoma: Can natural history be modified? Childs Nerv. Syst. 14, 317-321.
33. Massimino, M., Gandola, L., Cefalo, G., Lasio, G., Riva, D., Fossati-Bellani, F., Gianni, M.C., Luksch, R., Tesoro-Tess, J.D., and Lombardi, F. (2000) Management of medulloblastoma and ependymoma in infants: A single-institution long-term retrospective report. Childs Nerv. Syst. 16, 15-20.
34. Massimino, M., Spreafico, F., Cefalo, G., Riccardi, R., Tesoro-Tess, J.D., Gandola, L., Riva, D., Ruggiero, A., Valentini, L., Mazza, E., Genitori, L., Di Rocco, C., Navarria, P., Casanova, M., Ferrari, A., Luksch, R., Terenziani, M., Balestrini, M.R., Colosimo, C., and Fossati-Bellani, F. (2002) High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J. Clin. Oncol. 20, 4209-4216.
35. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Nakagawa, K., Hirashima, T., Tamanoi, M., Nitta, T., Yana, T., et al. (1994) Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J. Clin. Oncol. 12, 90-96.
36. McCormick, P.C., Torres, R., Post, K.D., and Stein, B.M. (1990) Intramedullary ependymoma of the spinal cord. J. Neurosurg. 72, 523-532.
37. Nadkarni, T.D., and Rekate, H.L. (1999) Pediatric intramedullary spinal cord tumors: Critical review of the literature. Childs Nerv. Syst. 15, 17-28.
38. Okamoto, H., Nagatomo, A., Kunitoh, H., Kunikane, H., and Watanabe, K. (1998) A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmallcell lung carcinoma. Cancer 82, 2166-2172.
39. Packer, R.J., Ater, J., Allen, J., Phillips, P., Geyer, R., Nicholson, H.S., Jakacki, R., Kurczynski, E., Needle, M., Finlay, J., Reaman, G., and Boyett, J.M. (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J. Neurosurg. 86, 747-754.
40. Pollack, I.F. (2004) Intramedullary spinal cord astrocytomas in children. Pediatr. Blood Cancer 43, 617-618.
41. 6-methylguanine. Cancer Res. 61, 53-58.
42. Raco, A., Esposito, V., Lenzi, J., Piccirilli, M., Delfini, R., and Cantore, G. (2005) Long term follow-up of intramedullary spinal cord tumors: A series of 202 cases. Neurosurgery 56, 972-981.
43. Shinkai, T., Arioka, H., Kunikane, H., Eguchi, K., Sasaki, Y., Tamura, T., Ohe, Y., Oshita, F., Nishio, M., Karato, A., et al. (1994) Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res. 54, 2636-2642.
44. Souid, A., Dubowy, R.L., Blaney, S.M., Hershon, L., Sullivan, J., McLeod, W.D., and Bernstein, M.L. (2003) Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin. Cancer Res. 9, 703-710.
45. Townsend, N., Handler, M., Fleitz, J., and Foreman, N. (2004) Intramedullary spinal cord astrocytomas in children. Pediatr. Blood Cancer 43, 629-632.
46. Turner, C.D., Gururangan, S., Eastwood, J., Bottom, K., Watral, M., Beason, R., McLendon, R.E., Friedman, A.M., Tourt-Uhlig, S., Miller, L.L., and Friedman, H.S. (2002) Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience. Neuro-Oncology 4, 102-108.
47. Vassal, G., Doz, F., Frappaz, D., Imadalou, K., Sicard, E., Santos, A., O'Quigley, J., Germa, C., Risse, M.L., Mignard, D., and Pein, F. (2003) A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J. Clin. Oncol. 21, 3844-3852.